CUHK Medicine

Name

CUHK Medicine

Legal name

Faculty of Medicine, The Chinese University of Hong Kong

Website

https://med.cuhk.edu.hk

Company type

Public

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Medical Education & Research

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYEDAHAGAJ

Health Informatics & Digital Health Programs

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

SECONDARYHLAAALAE

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAGAEAD

Genomics & Molecular Diagnostics (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAKAEAA

General Gastroenterology

Healthcare & Life Sciences/Specialist Medical Practice/Gastroenterology & Hepatology

Keywords

• Medical education
• Clinical research
• Translational medicine
• Microbiome therapeutics
• AI diagnostics

Headquarters

HQ city

Hong Kong

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Government Funding: Core operational funding from University Grants Committee and HKSAR Government for education, research, and infrastructure development including HK$3.3 billion for Teaching-Research Complex construction
2. Research Grants: Competitive external research funding from Hong Kong Research Grants Council, Greater Bay Area initiatives, and thematic funding including HK$80 million UGC Areas of Excellence funding for diabetes project
3. Philanthropy and Donations: Donations and charitable contributions supporting scholarships (Gerald Choa Memorial Fund awarded HK$2.6 million to 240+ students), research chairs, and facility development
4. Tuition and Fees: Academic programme fees for undergraduate and postgraduate medical education including MBChB, GPS, and continuing medical education programmes
5. Knowledge Transfer and Commercialization: Spin-off companies including GenieBiome and MicroSigX commercializing microbiome diagnostics and therapeutics, with products like stool-sample colon cancer test and microbiome formulas

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Core offering

CUHK Medicine is the Faculty of Medicine at The Chinese University of Hong Kong. It delivers undergraduate and postgraduate medical education (MBChB, Nursing, Pharmacy, Biomedical Sciences, Chinese Medicine, Public Health), conducts translational clinical research across microbiome science, precision medicine, AI in medicine, oncology, and ophthalmology, and commercialises discoveries through spin-off companies (GenieBiome, MicroSigX, OCUS Innovation) producing diagnostics and therapeutics such as MSX Metagenie, gut-microbe stool tests for colon cancer, and low-concentration atropine eye drops for myopia.

Product overview

CUHK Medicine is a medical school with a comprehensive portfolio of academic programmes and research-driven healthcare innovations. The institution offers undergraduate medical programmes (MBChB with GPS track, GET, DY2), nursing, biomedical sciences, Chinese medicine, pharmacy, public health, and other health-related programmes. Research excellence spans microbiome science (Microbiota I-Center/MagIC), diabetes management (JADE platform), myopia treatment (LAMP studies), and AI-driven diagnostics. The institution has commercialised multiple spin-off companies including GenieBiome (gut diagnostics), MicroSigX (MSX Metagenie), and OCUS Innovation (eye drops), along with live microbiome formulas (SIM01, SIM03, SIM05) targeting conditions from eczema to long COVID.

Differentiator

Problem solved

Functional benefit

Brands

• Microbiota I-Center (MagIC): Hong Kong's InnoCentre focused on developing novel diagnostics and therapeutics targeting the microbiome
• GenieBiome
• MicroSigX
• OCUS Innovation (HK)

Products and services

• Medicine (MBChB) Programme Six-year undergraduate medical degree programme (MBChB) with standard track, Graduate Entry Track, and Dynamic Year 2 entry options, designed for prospective medical students seeking world-class clinical education.
• Global Physician-Leadership Stream (GPS) Enhanced MBChB track offering international research exposure, humanitarian and leadership training, and articulation to Cambridge, Oxford, and MIT for further studies, targeted at high-achieving medical students.
• Bachelor of Nursing Programme Undergraduate nursing degree programme delivered through The Nethersole School of Nursing, ranked best in Asia and 5th globally.
• Biomedical Sciences Programme Undergraduate biomedical sciences degree programme offered through the School of Biomedical Sciences.
• Chinese Medicine Programme Undergraduate Chinese medicine degree programme offered through the School of Chinese Medicine.
• Bachelor of Pharmacy Programme Undergraduate pharmacy degree programme offered through the School of Pharmacy.
• Bachelor of Science in Public Health Undergraduate public health degree programme offered through The Jockey Club School of Public Health and Primary Care.
• Bachelor of Science in Gerontology Undergraduate gerontology degree programme focused on ageing population health.
• BSc in Community Health Practice Undergraduate community health practice degree programme.
• Microbiota I-Center (MagIC) Hong Kong InnoCentre established through collaboration between Professor Francis Chan and Professor Siew Ng, focused on developing novel diagnostics and therapeutics targeting the microbiome; gained international recognition during the COVID-19 pandemic for severity prediction research.
• MSX Metagenie (AI-Powered ASD Diagnostic) AI-powered multikingdom microbial biomarker technology for autism spectrum disorder diagnosis developed by MicroSigX spin-off, using machine learning across four kingdoms of microbial species; received FDA Breakthrough Device Designation.
• SIM01, SIM03, SIM05 Live Microbiome Formulas Oral microencapsulated live bacteria preparations using microencapsulation technology to promote gut colonisation: SIM01 for long COVID recovery, SIM03 for children with eczema, SIM05 for adults with eczema.
• GenieBiome Gut Microbe Diagnostics (Stool-Sample Colon Cancer Test) Non-invasive stool-sample test for early colon cancer detection with sensitivity over 90%, developed by GenieBiome as a more affordable alternative to traditional colonoscopy.
• Low-Concentration Atropine Eye Drops (LAMP) Low-concentration atropine eye drops (0.05%, 0.025%, 0.01%) for myopia prevention and treatment, commercialised through OCUS Innovation spin-off; demonstrated 67% reduction in myopia progression and 47% prevention of myopia onset in randomised placebo-controlled trials.
• Joint Asia Diabetes Evaluation (JADE) Program Web-based clinical program using proprietary technology to stratify diabetes risk, empower patient self-management, and promote doctor-patient communication, supported by territory-wide big-data evaluation of glucose-lowering agent outcomes.
• SCM06 Gut Microbiome Modulator Gut microbiome modulator designed to boost GABA neurotransmitter for autism spectrum disorder treatment; pilot clinical study showed 15-20% reduction in sensory and anxiety symptoms.
• Continuing Medical Education (CME) Continuing Medical Education programmes delivering knowledge updates, specialty training, and professional development to practicing doctors and healthcare professionals.

Quantifiable outcome

• Top 25 globally, Top 3 in Asia in medical school rankings
• +7 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered flagship, core, major and minor.

• GAME (Global Alliance of Medical Excellence)flagshipStrategic or Co-development Partner · 11 November 2024CU Medicine is a member institution of GAME, hosting the TEI Summit for Future Leaders in November 2024 with 100+ academics and students from 13 leading institutions across 7 countries. GAME member institutions include University of Bologna, Korea University, LMU Munich, Lund University, Monash University, and Nagoya University.
• Microbiota I-Center (MagIC)flagshipOthers · 9 August 2019Hong Kong's InnoCentre focused on developing novel diagnostics and therapeutics targeting the microbiome. Established through collaboration between Professor Francis Chan and Professor Siew Ng, gaining international recognition during pandemic for COVID-19 severity prediction research.
• GenieBiomecoreOthersCUHK biotechnology spin-off established in late 2019 by Professor Francis Chan and Professor Siew Ng. The GenieBiome Molecular and Microbiome Laboratory provides novel gut-microbe diagnostics including stool-sample test for early colon cancer detection.
• MicroSigXcoreOthersCUHK spin-off focused on developing innovative non-invasive diagnostic solutions including MSX Metagenie for ASD diagnosis, with planned commercial launch in Hong Kong (late 2025), Chinese Mainland, and United States.
• OCUS InnovationcoreOthersCUHK start-up involving Professor Jason Yam for commercialization of low-concentration atropine eye drops. Obtained Hong Kong Government support and admitted to Hong Kong Science and Technology Parks Incubation Programme.
• OUE Healthcare Limited (Qianhai)majorStrategic or Co-development PartnerCU Medicine offering management consultancy services for development of International Medical Centre at Prince Bay Hospital in Qianhai, Shenzhen. Facility positioned as pilot innovation centre, expected to open late 2025.
• Guangzhou Nansha GovernmentmajorStrategic or Co-development PartnerPartnership since April 2023 to shape Nansha into medical innovation hub. CU Medicine co-designing orthopaedic rehabilitation centre and developing service standards and staff training programmes for Nansha Central Hospital.
• University of CalgarymajorStrategic or Co-development PartnerPartnership supported by USD 2 million Helmsley Charitable Trust funding to create global repository on epidemiology of Crohn's Disease, focusing on Asian research into babies' gut microbiota.
• Hong Kong Science ParkcoreOthersAdjacent to CUHK campus, Teaching-Research Complex, and CUHK Medical Centre. Visit arranged for TEI Summit participants to showcase InnoCentres.
• 40+ NGOs and South Asian Community CentresminorOthersCollaboration with local non-governmental organisations and South Asian community centres for IMPACT programme, recruiting 52 community health worker trainees for cervical cancer screening promotion.

Scale indicators21 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Fudan University Shanghai Medical College: Top Chinese medical school with strong research output and clinical network. Comparable in scale, government funding model, and translational medicine focus.
• Tsinghua University School of Medicine: Rapidly-rising Chinese medical school with strong emphasis on AI in medicine and translational research. Comparable in AI-in-medicine curriculum focus and emerging top-tier research positioning.
• Peking University Health Science Center: Top Chinese medical school with strong research output, large clinical network, and translational research programs. Comparable in scale, government funding, and Asia-leading medical research profile.
• University of Hong Kong Li Ka Shing Faculty of Medicine: The other top-tier medical faculty in Hong Kong; directly comparable in clinical research, medical education, and academic medical center operations. Both compete for UGC funding, talent, and rankings in the same local market.
• University of Tokyo Faculty of Medicine: Top Japanese medical school with comparable scale, research breadth, and translational research infrastructure. Directly comparable in flagship medical faculty positioning in Asia.
• NUS Yong Loo Lin School of Medicine: Singapore's flagship medical school and a comparable top-3 Asian medical school with strong research output, spin-off activity, and translational medicine programs. Directly comparable in scale, funding model, and Asia-Pacific positioning.
• Seoul National University College of Medicine: Top Korean medical school with comparable research output, government funding mechanics, and translational medicine programs. Member of similar global academic alliances.

Emerging players

• GenieBiome: CUHK Medicine spin-off commercializing gut-microbe diagnostics. Listed as a peer because it represents the commercialized diagnostic arm of CUHK Medicine's microbiome research and is the vehicle through which the stool-sample colon cancer test is brought to market.

Broad incumbents

• Karolinska Institutet: Globally-ranked medical school with strong research output and Nobel-affiliated research. Comparable in world-leading medical research positioning, though operating at a larger scale and European funding model.
• Stanford University School of Medicine: Global top medical school with strong AI in medicine, biotech spin-off ecosystem, and translational research. Comparable in AI-medicine leadership and commercialization model, though at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CUHKMedicine
• YouTubeyoutube.com/@CUHKMed
• Facebookfacebook.com/CUMedicine
• LinkedInlinkedin.com/school/cuhkmedicine
• Instagraminstagram.com/cuhkmedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CUHK Medicine